ArticleComputational and structural biotechnology journal2025
MiDNE a tool for Multi-omics genes and drugs interactions discovery.
Article in Computational and structural biotechnology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Multi-omics integration identifiesTranslational andrology and urology · 2026Article
- Artemis: Harnessing Knowledge Graphs for Next-Generation Drug Target Prioritization.Computational and structural biotechnology journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The availability of models representing molecular interactions in complex pathologies is essential for understanding their molecular setup and identifying therapeutic vulnerabilities. In this context, the advent of high-throughput technologies has enabled the rapid and cost-effective profiling of multiple omics layers, driving a paradigm shift from generalized models to disease-specific, context-aware modeling approaches. While the analysis of individual omics layers can provide information about specific aspects of cellular biology for a given disease, it often fails to capture complex interactions among molecules and drugs operating across different regulatory levels. Here, we introduce MiDNE (Multi-omics genes and Drugs Network Embedding), a novel computational framework that integrates experimental multi-omics data with pharmacological knowledge to uncover disease specific multi-omics gene and drug interactions. MiDNE integrates omics-specific networks, derived from experimental data, with known drug interactors in a multiplex heterogeneous network. It applies a network embedding procedure based on the random walk with restart algorithm to project genes and drugs into a shared multi-omics latent space, enabling gene-drug clustering and neighborhood search. We demonstrate the potential of MiDNE on Breast Invasive Carcinoma and Glioblastoma multiforme, by integrating gene expression, methylation, proteomic, and copy number variation profiles with curated drug-target interactions. By providing multilayer and disease-specific views of gene and drug interactions, MiDNE facilitates the discovery of actionable gene-drug relationships and the development of precision pharmacological strategies. MiDNE is available as both an open-source R package and a Shiny web application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.